Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 27, 2012

Heterogeneous FDG–PET Responses Prognostic in Dabrafenib-Treated Metastatic Melanoma

European Journal of Cancer

 

Additional Info

European Journal of Cancer
18F-Labelled Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) Heterogeneity of Response is Prognostic in Dabrafenib Treated BRAF Mutant Metastatic Melanoma
Eur. J. Cancer 2012 Sep 17;()2012 Sept 17, MS Carlino, CAB Saunders, LE Haydu, et al

Further Reading